Pharmaceuticals

Inflectra Market 2026–2035 strengthening biosimilar adoption

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Inflectra Market Between 2026 And 2030?

The expansion observed historically stemmed from several factors, including the elevated expense of originator TNF inhibitors, the granting of regulatory approvals for biosimilars, the increasing burden of autoimmune diseases, the acceptance into hospital formularies, and the cost-saving approaches implemented by payers.

The anticipated growth during the forecast period is attributable to regulations favoring biosimilars, enhanced patient access to biologics, an uptick in inflammatory diseases, competitive pricing pressures, and growing physician understanding.

Significant trends expected throughout the forecast period involve the increasing adoption of biosimilars, switching from originator biologics primarily due to cost, the expansion of treatments for autoimmune diseases, physician confidence regarding biosimilar safety, and biosimilar procurement led by hospitals.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20102&type=smp

What Drivers Are Influencing The Inflectra Market?

The growing occurrence of autoimmune conditions is anticipated to fuel the expansion of the inflectra market in the future. These conditions involve the immune system erroneously targeting healthy cells, resulting in inflammation and harm to diverse tissues and organs. The rise in autoimmune disease prevalence stems from shifts in diet, pollutant exposure, lifestyle choices, and climate change. Autoimmune diseases influence inflectra by boosting the need for effective treatment choices, as a greater number of patients look for therapies like inflectra, vital for handling conditions such as rheumatoid arthritis and Crohn’s disease through its action of blocking tumor necrosis factor-alpha (TNF-a) to alleviate inflammation. For example, data from September 2023, provided by the IBD Clinical and Research Centre, a Canada-based organization dedicated to enhancing the lives of patients with Crohn’s disease and ulcerative colitis, indicated that in 2023 more than 320,000 Canadians were living with inflammatory bowel disease (IBD), showing a prevalence of 825 per 100,000. With the prevalence increasing by 2.44% annually, projections suggest that 1.1% of Canada’s population, amounting to 470,000 individuals, will be affected by IBD by 2035. Consequently, the rising prevalence of autoimmune diseases is fueling the expansion of the inflectra market.

Which Market Segments Are Examined In The Inflectra Market Study?

The inflectra market covered in this report is segmented –

1) By Patient Demographics: Pediatric Patients, Adult Patients

2) By Application: Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, Other Indications

3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies

Which Trends Are Influencing The Inflectra Market?

A prominent trend in the inflectra market focuses on creating innovative products, such as subcutaneous infliximab biosimilars, to offer a convenient and effective maintenance treatment option for patients with inflammatory bowel disease through a subcutaneous formulation. These subcutaneous infliximab biosimilars represent an injectable form of infliximab, providing an easier administration method for addressing autoimmune diseases. For example, in October 2023, Celltrion USA, the US-based subsidiary of the biopharmaceutical company Celltrion, announced the FDA approval of ZYMFENTRA (infliximab-dyyb). This product stands as the first and only subcutaneous formulation of infliximab intended for the maintenance treatment of moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC) in adults. This novel subcutaneous formulation ensures stable elevated serum infliximab levels, presenting a more convenient and flexible administration choice for both patients and healthcare providers. The approval holds significant weight as it addresses the daily burden associated with managing inflammatory bowel disease and enhances patient control over their treatment regimen.

Who Are The Primary Competitors In The Inflectra Market?

Major companies operating in the inflectra market are Celltrion Inc

Read the full inflectra market report here:

https://www.thebusinessresearchcompany.com/report/inflectra-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Inflectra Market?

Europe was the largest region in the inflectra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflectra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Inflectra Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20102&type=smp

Browse Through More Reports Similar to the Global Inflectra Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795